{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:42:46Z","timestamp":1767181366284,"version":"build-2238731810"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1011716","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000}}],"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zhitao Biomedicine","award":["startup research fund"],"award-info":[{"award-number":["startup research fund"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["3210063"],"award-info":[{"award-number":["3210063"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune-based therapy is a promising type of treatment for hepatocellular carcinoma (HCC) but has only been partially successful due to the high heterogeneity in HCC tumor. The differences in the degree of tumor cell progression and in the activity of tumor immune microenvironment could lead to varied clinical outcome. Accurate subgrouping for recurrence risk is an approach to address the issue of such heterogeneity. It remains under investigation as whether integrating quantitative whole slide image (WSI) features with the expression profile of immune marker genes can improve the risk stratification, and whether clinical outcome prediction can assist in understanding molecular biology that drives the outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included a total of 231 patients from the Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) project. For each patient, we extracted 18 statistical metrics corresponding to a global region of interest and 135 features regarding nucleus shape from WSI. A risk score was developed using these image features with high-dimensional survival modeling. We also introduced into the model the expression profile of 66 representative marker genes relevant to currently available immunotherapies. We stratified all patients into higher and lower-risk subgroup based on the final risk score selected from multiple models generated, and further investigated underlying molecular mechanisms associated with the risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One WSI feature and three immune marker genes were selected into the final recurrence-free survival (RFS) prediction model following the best integrated modeling framework. The resultant score showed a significantly improved prediction performance on the test dataset (mean time-dependent AUCs = 0.707) as compared to those of other types (e.g: mean time-dependent AUCs of AJCC tumor stage = 0.525) of input data integration. To assess that the risk score could provide a higher-resolution risk stratification, a lower-risk subgroup (or a higher-risk subgroup) was arbitrarily assigned according to score falling below (or above) the median score. The lower risk subgroup had significantly longer median RFS time than that of the higher-risk patients (median RFS = 903 vs. 265 days, log-rank test p-value&lt; 0.0001). Additionally, the higher-risk subgroup, in contrast to the lower-risk patients were characterized with a significant downregulation of immune checkpoint genes, suppressive signal in tumor immune response pathways, and depletion of CD8 T cells. These observations for the higher-risk subgroup suggest that new targets for adoptive or checkpoint-based combined systemic therapies may be useful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We developed a novel prognostic model to predict RFS for HCC patients, using one feature that can be automatically extracted from routine histopathological images, as well as the expression profiles of three immune marker genes. The methodology used in this paper demonstrates the feasibility of developing prognostic models that provide both useful risk stratification along with valuable biological insights into the underlying characteristics of the subgroups identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pcbi.1011716","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T13:31:25Z","timestamp":1703856685000},"page":"e1011716","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrence risk stratification of hepatocellular carcinomas based on immune gene expression and features extracted from pathological images"],"prefix":"10.1371","volume":"19","author":[{"given":"Tao","family":"Ding","sequence":"first","affiliation":[]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[]},{"given":"Jiu","family":"Mo","sequence":"additional","affiliation":[]},{"given":"Gregory","family":"Alexander","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-6876","authenticated-orcid":true,"given":"Jialu","family":"Li","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"issue":"10127","key":"pcbi.1011716.ref001","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma.","volume":"391","author":"A Forner","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"pcbi.1011716.ref002","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","article-title":"Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis","volume":"261","author":"P Tabrizian","year":"2015","journal-title":"Ann Surg"},{"issue":"2","key":"pcbi.1011716.ref003","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cld.2015.01.007","article-title":"Surgical resection and liver transplantation for hepatocellular carcinoma","volume":"19","author":"ME Akoad","year":"2015","journal-title":"Clin Liver Dis"},{"issue":"2","key":"pcbi.1011716.ref004","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.sla.0000197706.21803.a1","article-title":"Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications","volume":"243","author":"N Portolani","year":"2006","journal-title":"Ann Surg"},{"issue":"3","key":"pcbi.1011716.ref005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma.","volume":"19","author":"JM Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"pcbi.1011716.ref006","first-page":"1327","volume-title":"Electronic address wbe, Cancer Genome Atlas Research N. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell","author":"Cancer Genome Atlas Research Network","year":"2017"},{"issue":"1","key":"pcbi.1011716.ref007","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12885-021-07916-3","article-title":"A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy","volume":"21","author":"D Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"pcbi.1011716.ref008","doi-asserted-by":"crossref","first-page":"1019638","DOI":"10.3389\/fimmu.2022.1019638","article-title":"Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma.","volume":"13","author":"Q Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"pcbi.1011716.ref009","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41523-023-00545-y","article-title":"Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer","volume":"9","author":"Y Chen","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"pcbi.1011716.ref010","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s12276-020-0422-0","article-title":"Single-cell transcriptomics in cancer: computational challenges and opportunities","volume":"52","author":"J Fan","year":"2020","journal-title":"Exp Mol Med"},{"issue":"1","key":"pcbi.1011716.ref011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13059-020-1926-6","article-title":"Eleven grand challenges in single-cell data science","volume":"21","author":"D Lahnemann","year":"2020","journal-title":"Genome Biol"},{"issue":"3","key":"pcbi.1011716.ref012","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/hep.29904","article-title":"Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification","volume":"68","author":"Y Kurebayashi","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"pcbi.1011716.ref013","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12957-020-01909-5","article-title":"Combining texture features of whole slide images improves prognostic prediction of recurrence-free survival for cutaneous melanoma patients.","volume":"18","author":"Y Peng","year":"2020","journal-title":"World J Surg Oncol"},{"issue":"7","key":"pcbi.1011716.ref014","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1245\/s10434-019-08190-1","article-title":"Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning","volume":"27","author":"H Liao","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"pcbi.1011716.ref015","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/gutjnl-2020-320930","article-title":"Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning","volume":"70","author":"JY Shi","year":"2021","journal-title":"Gut"},{"issue":"1","key":"pcbi.1011716.ref016","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","article-title":"A threshold selection method from gray-level histograms","volume":"9","author":"N. Otsu","year":"1979","journal-title":"IEEE transactions on systems, man, and cybernetics"},{"issue":"4","key":"pcbi.1011716.ref017","first-page":"291","article-title":"Quantification of histochemical staining by color deconvolution.","volume":"23","author":"AC Ruifrok","year":"2001","journal-title":"Anal Quant Cytol Histol"},{"issue":"1","key":"pcbi.1011716.ref018","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1038\/s41598-019-38813-2","article-title":"Segmentation of Heavily Clustered Nuclei from Histopathological Images.","volume":"9","author":"M Abdolhoseini","year":"2019","journal-title":"Sci Rep."},{"issue":"3","key":"pcbi.1011716.ref019","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1134\/S1054661811020271","article-title":"and Polovinkin, A.N. New object detection features in the OpenCV library","volume":"21","author":"PN Druzhkov","year":"2011","journal-title":"Pattern Recognition and Image Analysis"},{"issue":"21","key":"pcbi.1011716.ref020","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational Radiomics System to Decode the Radiographic Phenotype","volume":"77","author":"JJM van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"pcbi.1011716.ref021","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","article-title":"The lasso method for variable selection in the Cox model","volume":"16","author":"R. Tibshirani","year":"1997","journal-title":"Stat Med"},{"issue":"4","key":"pcbi.1011716.ref022","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.","volume":"15","author":"FE Harrell","year":"1996","journal-title":"Stat Med."},{"issue":"2","key":"pcbi.1011716.ref023","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"PJ Heagerty","year":"2000","journal-title":"Biometrics"},{"issue":"1","key":"pcbi.1011716.ref024","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"MD Robinson","year":"2010","journal-title":"Bioinformatics"},{"issue":"3","key":"pcbi.1011716.ref025","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"MD Robinson","year":"2010","journal-title":"Genome Biol"},{"issue":"2","key":"pcbi.1011716.ref026","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/gb-2010-11-2-r14","article-title":"Gene ontology analysis for RNA-seq: accounting for selection bias","volume":"11","author":"MD Young","year":"2010","journal-title":"Genome Biol"},{"key":"pcbi.1011716.ref027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"EY Chen","year":"2013","journal-title":"BMC Bioinformatics"},{"issue":"43","key":"pcbi.1011716.ref028","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"A Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1011716.ref029","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling Tumor Infiltrating Immune Cells with CIBERSORT.","volume":"1711","author":"B Chen","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"7","key":"pcbi.1011716.ref030","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"AM Newman","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"1\u20132","key":"pcbi.1011716.ref031","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Y Benjamini","year":"2001","journal-title":"Behav Brain Res"},{"issue":"7","key":"pcbi.1011716.ref032","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/archsurg.1994.01420310070012","article-title":"Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years","volume":"129","author":"MF Chen","year":"1994","journal-title":"Arch Surg"},{"issue":"6","key":"pcbi.1011716.ref033","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1028::AID-CNCR4>3.0.CO;2-A","article-title":"Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients.","volume":"82","author":"M Lise","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"pcbi.1011716.ref034","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00000658-200203000-00009","article-title":"Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation","volume":"235","author":"RT Poon","year":"2002","journal-title":"Ann Surg"},{"issue":"1","key":"pcbi.1011716.ref035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41467-019-14050-z","article-title":"Intratumoral heterogeneity and clonal evolution in liver cancer","volume":"11","author":"B Losic","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"pcbi.1011716.ref036","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/hep4.1197","article-title":"A Survey of Molecular Heterogeneity in Hepatocellular Carcinoma.","volume":"2","author":"J Jovel","year":"2018","journal-title":"Hepatol Commun."},{"issue":"8","key":"pcbi.1011716.ref037","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-14-2602","article-title":"Intratumor molecular and phenotypic diversity in hepatocellular carcinoma","volume":"21","author":"JC Nault","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"pcbi.1011716.ref038","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying Cancers Based on T-cell Infiltration and PD-L1","volume":"75","author":"MW Teng","year":"2015","journal-title":"Cancer Res"},{"issue":"6","key":"pcbi.1011716.ref039","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1159\/000512170","article-title":"Limited Impact of Anti-PD-1\/PD-L1 Monotherapy for Hepatocellular Carcinoma","volume":"9","author":"M. Kudo","year":"2020","journal-title":"Liver Cancer"},{"issue":"1","key":"pcbi.1011716.ref040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma.","volume":"7","author":"JM Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"pcbi.1011716.ref041","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2006-11-010389","article-title":"Suppression of T-cell functions by human granulocyte arginase","volume":"108","author":"M Munder","year":"2006","journal-title":"Blood"},{"issue":"44","key":"pcbi.1011716.ref042","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"H Alshetaiwi","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"pcbi.1011716.ref043","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40425-019-0504-5","article-title":"Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity","volume":"7","author":"JJ Miret","year":"2019","journal-title":"J Immunother Cancer"},{"key":"pcbi.1011716.ref044","first-page":"938","volume":"11","author":"TM Grzywa","year":"2020","journal-title":"Myeloid Cell-Derived Arginase in Cancer Immune Response. Front Immunol"},{"key":"pcbi.1011716.ref045","first-page":"e16713","volume":"38","author":"15_suppl","year":"2020","journal-title":"The oncogenic role of ARG2 in hepatocellular carcinoma"},{"key":"pcbi.1011716.ref046","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","author":"C Montironi","year":"2022","journal-title":"Gut"},{"issue":"20","key":"pcbi.1011716.ref047","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"RS Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"pcbi.1011716.ref048","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.","volume":"38","author":"RS Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"pcbi.1011716.ref049","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.","volume":"27","author":"J Xu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"15","key":"pcbi.1011716.ref050","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials","volume":"26","author":"D Shi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"pcbi.1011716.ref051","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study.","volume":"22","author":"Z Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"pcbi.1011716.ref052","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics","volume":"173","author":"J Liu","year":"2018","journal-title":"Cell"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1011716","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T13:42:04Z","timestamp":1704980524000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011716"}},"subtitle":[],"editor":[{"given":"Gang","family":"Peng","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":52,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1011716","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}